|
3.1 PRÉVENTION - TABAC
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|
Unlock ways to share data on peer review [Nature]
|
|
|
|
|
|
Publishers, too, could rely on shared protocols to anonymize and manage data, reducing costs and reputational risk. Indeed, an agreement to share data on peer review could become a clear marker of legitimacy in a world increasingly plagued by predatory journals.
|
|
|
|
|
|
|
Invest 5% of research funds in ensuring data are reusable [Nature]
|
|
|
|
|
|
Funders hold the stick: they should disburse no further funding without a properly reviewed and budgeted data-stewardship plan. The carrot is that FAIR data allow much more effective artificial intelligence (FAIR can also mean ‘fully AI ready’), which will open up unprecedented research opportunities and increase reproducibility.
|
|
|
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|